FRIDAY, Feb. 8 (HealthDay News) -- Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.
Latest Cancer News
The disease, a form of blood cancer, affects some 21,700 Americans annually and nearly 10,700 die from it each year, the agency said Friday in a news release.
Pomalyst is designed to spur the immune system to destroy and inhibit cancer cells, the FDA said. The drug's safety and effectiveness were evaluated in a clinical study of 221 people with advanced multiple myeloma.
The drug is marketed by Celgene, based in Summit, N.J.
-- Scott Roberts
Copyright © 2013 HealthDay. All rights reserved.
Subscribe to MedicineNet's Cancer Report Newsletter